Objectives: Human herpesvirus 6 is associated with a variety of complications in immunocompromised patients, but no studies have systematically and comprehensively assessed the impact of human herpesvirus 6 reactivation, and its interaction with cytomegalovirus, in ICU patients. Design: We prospectively assessed human herpesvirus 6 and cytomegalovirus viremia by twice-weekly plasma polymerase chain reaction in a longitudinal cohort study of 115 adult, immunocompetent ICU patients. The association of human herpesvirus 6 and cytomegalovirus reactivation with death or continued hospitalization by day 30 (primary endpoint) was assessed by multivariable logistic regression analyses. Setting: This study was performed in trauma, medical, surgical, and cardiac ICUs at two separate hospitals of a large tertiary care academic medical center. Patients: A total of 115 cytomegalovirus seropositive, immunocompetent adults with critical illness were enrolled in this study. Interventions: None. Measurements and Main Results: Human herpesvirus 6 viremia occurred in 23% of patients at a median of 10 days. Human herpesvirus 6B was the species detected in eight samples available for testing. Most patients with human herpesvirus 6 reactivation also reactivated cytomegalovirus (70%). Severity of illness was not associated with viral reactivation. Mechanical ventilation, burn ICU, major infection, human herpesvirus 6 reactivation, and cytomegalovirus reactivation were associated with the primary endpoint in unadjusted analyses. In a multivariable model adjusting for mechanical ventilation and ICU type, only coreactivation of human herpesvirus 6 and cytomegalovirus was significantly associated with the primary endpoint (adjusted odds ratio, 7.5; 95% CI, 1.9-29.9; p = 0.005) compared to patients with only human herpesvirus 6, only cytomegalovirus, or no viral reactivation.
H uman herpesvirus 6 (HHV-6) is a ubiquitous β-herpesvirus that infects the majority of the population and establishes lifelong latency in a wide variety of host cells (1) . Reactivation from latency rarely occurs in immunocompetent hosts but is common in immunocompromised patients, where it is associated with a variety of adverse events, including fever, rash, CNS disease, graft rejection, pneumonitis, increased risk for infection, and increased allcause mortality (2) (3) (4) (5) . Patients with critical illness can develop immunologic impairment that facilitates reactivation of latent herpes viruses (6) . Cytomegalovirus (CMV), a closely related β-herpesvirus, has been shown to frequently reactivate in ICU patients and is associated with adverse outcomes (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Multiple studies in transplant patients have demonstrated coreactivation of HHV-6 and CMV (19, 20) . However, no prospective studies have comprehensively evaluated the clinical impact of HHV-6, and its interaction with CMV, in critically ill ICU patients.
Two cross-sectional studies reported frequent HHV-6 reactivation in ICU patients (53-54%) but did not find an independent association with adverse outcomes (21, 22) . A recent prospective study assessing reactivation of multiple viruses in ICU patients also found frequent HHV-6 reactivation that was associated with longer ICU length of stay but not mortality (23) . These three studies are the only reported investigations of HHV-6 in ICU patients to our knowledge and have important limitations that include study design, restrictive patient populations, qualitative or less sensitive polymerase chain reaction (PCR) assays, use of cellular blood samples that may contain latent virus in lymphocytes (1) , possible inclusion of patients with chromosomally integrated HHV-6, and lack of comprehensive multivariable statistical analyses to control for potential confounders. Only one study performed HHV-6 species typing and reported all reactivation events to be due to species A (21) . Given that HHV-6A and HHV-6B were recently classified as distinct species with unique biologic and epidemiologic characteristics (24) , species classification is important for the study of these viruses.
To more accurately define the incidence, risk factors, characteristics, and significance of HHV-6 reactivation in a diverse population of critically ill adults, as well as the association of HHV-6 and CMV coreactivation with clinically important outcomes, we tested for HHV-6 viremia in a previously characterized prospective cohort of CMV seropositive, immunocompetent adult ICU patients (12) .
MATERIALS AND METHODS

Study Design
We assessed HHV-6 viremia in twice-weekly collected plasma samples obtained from a previously characterized prospective cohort of 120 immunocompetent adults admitted to six ICUs (burn ICU [BICU], cardiac ICU [CICU], medical ICU [MICU], and trauma ICU [TICU]) at two hospitals of a large U.S. tertiary care academic medical center between 2004 and 2006 (12) . In the original cohort, twiceweekly quantitative plasma PCR testing for CMV and prospective assessment of clinical endpoints were performed from time of admission to ICU until hospital discharge. Plasma samples were stored at -70°C for subsequent testing. Samples were available for HHV-6 testing in 115 patients for this secondary analysis.
Only patients who were newly admitted to the ICU from home or baseline residential setting were included. Patients underwent clinical assessments using standardized data collection forms. Clinical information was collected prospectively by study personnel who were blinded to HHV-6 and CMV results. Clinical teams caring for patients did not know HHV-6 or CMV PCR results; testing was performed after finalization of all clinical endpoints by the blinded data extractors. Patients were followed up until death or hospital discharge. Deaths occurring within 90 days after discharge from the hospital were assessed using state and national death registry data. No CMV-specific therapy was given to study patients. The study was approved by the human subjects division at the University of Washington, and written informed consent was obtained from study participants or their legally authorized representatives. (12) .
Inclusion and Exclusion Criteria
HHV-6 and CMV Assays
DNA was extracted from plasma samples using the QIAamp 96 DNA Blood Kit (Qiagen, Santa Clarita, CA). Detection of HHV-6 DNA was performed using a real-time quantitative fluorescent probe PCR assay as previously described (25) . Detection of one copy of HHV-6 DNA/reaction (25 copies/ mL of plasma) was the lower limit of detection of our assay and considered a positive test. A highly conserved region of the U94 gene in HHV-6A and HHV-6B was amplified and used to distinguish species. Testing for chromosomally integrated HHV-6 was considered for patients with suggestive test results (viral load > 3.5 log 10 copies/mL or persistent levels > 100 copies/mL in > 80% of plasma samples) (26) . CMV PCR test results from our original publication were used for this study, and testing was performed as previously described (27) .
Statistical Analysis
Descriptive statistics for patient HHV-6 and CMV PCR results are presented using percentages or median and range values. Cumulative incidence estimates for reactivation of HHV-6 considered death or discharge from the hospital as competing risk events. First, we performed logistic regression analyses of risk factors for HHV-6 reactivation by considering baseline variables at the time of ICU admission, including age, race, unit, sex, Acute Physiology and Chronic Health Evaluation (APACHE) II score, blood transfusion, and ventilator use. A similar analysis was previously reported for CMV in the original cohort (12) .
Next, we performed a univariate analysis of risk factors associated with a composite endpoint of continued hospitalization or death by day 30 (primary endpoint) using baseline and hospital stay variables that occurred prior to the endpoint. Our primary goal was to determine the association between viral reactivation and length of stay as an indirect metric for a clinically significant impact. Mortality was included in the endpoint to reduce the potential effect of early deaths on assessment of the relationship between viral reactivation and duration of hospitalization. Hospital variables consisted of HHV-6 or CMV DNA detection, occurrence of major infection, and number of hospital days during which blood transfusions or mechanical ventilation were administered. Proportion of days transfused or ventilated were calculated by dividing the sum of days a patient was transfused or ventilated by the total number of days of follow-up, up to a maximum of 30 days. We did not evaluate the quantitative association between viral load and the endpoint given that only six patients had HHV-6 viral load greater than 1,000 copies/mL.
Multivariable models were built to assess the association of HHV-6 and CMV viremia with the primary endpoint, adjusting for baseline covariates (present at the time of ICU admission). HHV-6 and CMV reactivation were modeled as dichotomous variables and coded as positive with any level of viral detection before the primary endpoint. Initial models were built examining the independent association of any HHV-6 or any CMV reactivation with the primary endpoint (HHV-6 and CMV covariates were not included in the same model in this analysis). Due to the high level of coreactivation of these viruses (most patients with HHV-6 reactivation also had CMV reactivation), we fit a model with a combined covariate to assess the joint and separate effects of HHV-6 and CMV. This variable for HHV-6 and CMV reactivation had four levels: 1) patients with only HHV-6 and no CMV reactivation; 2) patients with only CMV and no HHV-6 reactivation; 3) patients with reactivation of both viruses; and 4) patients without reactivation of either virus. Since some of these categories had low numbers, we created an additional model that considered a variable for HHV-6 and CMV reactivation with only two levels: 1) patients with coreactivation of both viruses and 2) patients with reactivation of only HHV-6, only CMV, or neither virus. Potential interaction was examined between HHV-6 and CMV.
Logistic regression models with odds ratios (ORs) and corresponding 95% CIs were used for these analyses. Risk factors that were significant at p value less than 0.1 in univariate analysis were entered into multivariable models that were limited to three or four clinically relevant factors due to the number of events or subjects. Statistical significance was defined as p value less than 0.05. SAS version 9.2 (SAS Institute, Cary, NC) was used for all analyses.
RESULTS
Study Population
A total of 115 CMV seropositive adult ICU patients were included in the final analysis; five patients from the original cohort (12) did not have samples available for testing and were excluded. Characteristics of the study population are summarized in Table 1 . The primary endpoint of continued hospitalization or death by 30 days occurred in 44 patients (38%). 
Characteristics of HHV-6 and CMV Reactivation
The characteristics of HHV-6 and CMV reactivation are displayed in Table 2 . The cumulative incidence estimate of HHV-6 viremia at any level was 23% (27 of 115; 95% CI, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] and occurred at a median of 10 days (range, 0-75 d). Although duration of consecutive positive tests for HHV-6 from the time of first detection was short (median, 1 d; range, 1-4) compared with CMV, 22% of these patients had subsequent detection of HHV-6 during the study period. When stratified by ICU, the cumulative incidence estimates of HHV-6 viremia at any level were 42% (95% CI, 20-67), 16% (95% CI, 3-40), 22% (95% CI, , and 20% (95% CI, in the BICU, CICU, MICU, and TICU, respectively (Fig. 1) . Most patients with HHV-6 reactivation also reactivated CMV (70%), and 49% with CMV reactivation also reactivated HHV-6 ( Fig. 2) . Time to first detection of HHV-6 and CMV was similar ( Table 2) . Only 5% of patients had HHV-6 viral load greater than 1,000 copies/mL. HHV-6 species typing was performed in eight patients and all had species B. No patients had virologic findings suggestive of chromosomally integrated HHV-6 based on previously published criteria (26) .
Risk Factors for HHV-6 Reactivation
Univariate logistic regression analysis of baseline characteristics identified only male sex as a significant risk factor for HHV-6 reactivation (OR, 3.5; 95% CI, 1.2-10.1; p = 0.02), as was previously shown for CMV reactivation. APACHE II score at admission was not associated with either HHV-6 or CMV reactivation. No other variables met criteria for inclusion into a multivariable model.
Risk Factors for Death or Continued Hospitalization
Descriptively, the primary composite endpoint of death or continued hospitalization by 30 days occurred in 50% of patients who reactivated only HHV-6, 45% of patients who reactivated only CMV, 76% of patients who reactivated both HHV-6 and CMV, and 41% of those who never reactivated either virus.
Only HHV-6 and/or CMV reactivation prior to the endpoint was considered in these analyses. A univariate analysis examining associations of baseline and hospital stay variables with the primary endpoint showed significantly elevated risks for subjects with BICU admission (OR, 48.4; 95% CI, 6.2-381.1; p < 0.001), mechanical ventilation at baseline (OR, 4.8; 95% CI, 1.5-15; p = 0.007), development of a major infection (OR, 2.4; 95% CI, 1.0-5.4; p = 0.04), HHV-6 viremia at any level (OR, 5.0; 95% CI, 1.9-12.9; p = 0.001), and CMV viremia at any level (OR, 3.7; 95% CI, 1.6-8.5; p = 0.002) ( Table 3 ).
In a multivariable logistic regression model adjusting for ICU type and mechanical ventilation at baseline, HHV-6 reactivation at any level, without adjustment for CMV, was associated with the primary endpoint (adjusted [a]OR, 3.5; 95% CI, 1.2-10.3; p = 0.03) (Table 3) . Similarly, CMV reactivation at any level, without adjustment for HHV-6, was associated with the primary endpoint as we previously demonstrated (aOR, 3.4; 95% CI, 1.3-8.9; p = 0.01).
However, after adjusting for HHV-6 reactivation, any CMV reactivation was no longer significantly associated with the endpoint (data not shown). Interaction between CMV reactivation and HHV-6 reactivation was not significant (p = 0.30). Since a large proportion of subjects reactivated both HHV-6 and CMV (Fig. 2) , we used two approaches to better understand the associations of each virus versus combined viruses with the primary endpoint. First, we used a model incorporating a viral reactivation variable stratified into four levels, including: 1) only HHV-6 reactivation (n = 8); 2) only CMV reactivation (n = 20); 3) coreactivation of both viruses (n = 19); 4) or reactivation of neither virus (n = 68). In this model, only coreactivation of both viruses was significantly associated with the primary endpoint (aOR, 7.5; 95% CI, 1.9-29.9; p = 0.005) ( Table 4 ). Second, since there were relatively small numbers in some levels of this model, we also created a model using a viral reactivation variable with only two levels: 1) patients with coreactivation of HHV-6 and CMV and 2) a combined category that included patients with reactivation of only HHV-6, only CMV, or neither virus. This model also demonstrated a significant association of coreactivation of HHV-6 and CMV with the primary endpoint (aOR, 6.5; 95% CI, 1.7-24.7; p = 0.006) ( Table 4 ) compared to patients with only HHV-6, only CMV, or no viral reactivation.
DISCUSSION
In this prospective study of a diverse cohort of immunocompetent ICU patients, we demonstrate frequent HHV-6 reactivation and the novel finding that patients with coreactivation of both HHV-6 and CMV have the greatest risk for death or continued hospitalization by day 30. Eight tested samples were HHV-6B, which is the species identified in the majority of reactivation events in immunocompromised patients (1, 3) . Coreactivation of CMV occurred in the majority of patients with HHV-6 reactivation. This updated analysis of our initial study, which showed an association of CMV reactivation with prolonged hospitalization or death (12) , advances understanding of particularly high-risk patient groups by considering HHV-6 in the models. Increased rates of adverse events in patients with coreactivation of HHV-6 and CMV have been reported in other settings and are speculated to be due to mechanistic interactions between the two viruses (28, 29) .
There are several biologically plausible mechanisms to explain frequent coreactivation of HHV-6 and CMV and a possible causal association with prolonged hospitalization or death. One of the original descriptions of concurrent detection of multiple herpesviruses was reported in 1979 for CMV and EBV in healthy patients with mononucleosis syndromes (30) . The authors postulated that depressed cellular immunity due to infection with one virus, as well as nonspecificity of viral DNA polymerase activity, might facilitate reactivation of the other. Similarly, HHV-6 has been associated with an increased risk for CMV reactivation (3) and clinically manifest CMV disease (31) . HHV-6 and CMV are closely related β-herpesviruses that can cause disease of a variety of organ systems in immunocompetent and immunocompromised patients. Direct viral-mediated tissue injury (e.g., pneumonia) (32) and immunomodulatory effects leading to an increased risk for secondary infections (33, 34) are some mechanisms through which CMV could mediate worse clinical outcomes in ICU patients. Similar mechanisms are possible for HHV-6, which has also been associated with lung injury (4, 5) and immune dysfunction (33, 34) in immunocompromised patients. HHV-6 might also contribute to ICU delirium, which has been associated with prolonged ICU length of stay and overall hospitalization, as well as long-term cognitive impairment and increased mortality (35, 36) . This potential mechanistic link is supported by results from a prospective trial in hematopoietic cell transplantation (HCT) recipients showing an independent association between HHV-6 reactivation and delirium (37) . The cognitive deficits and pathologic changes seen in ICU patients with delirium are similar to the manifestations of HHV-6-associated CNS disease in HCT recipients (1, 38) . Since HHV-6 and CMV each have similar pathogenic effects, it follows that coreactivation of both viruses might be associated with worse outcomes than reactivation of either virus alone, as demonstrated in this study. Testing for viral detection in other compartments (e.g., bronchoalveolar lavage fluid and cerebrospinal fluid) may be important in future studies.
This study has several strengths, including the prospective design, inclusion of diverse ICU populations, use of a sensitive and quantitative PCR method, use of plasma to avoid detection of latent virus, species typing, exclusion of chromosomally integrated HHV-6, blinded clinical endpoints to minimize bias, and comprehensive statistical analyses with an adequate number of clinically relevant endpoints. The primary endpoint considered events occurring up to 30 days after ICU admission because all patients had equal follow-up assessments for viral reactivation during this period, and it took into consideration a biologically relevant time lag for HHV-6 or CMV effects. Furthermore, establishing a discrete endpoint of 30 days minimized a potential spurious association between viral reactivation and increased length of stay as a consequence of increased opportunity for detection in people with longer hospitalizations. The study also has potential limitations. Although more than 98% of people are seropositive for HHV-6 (1), only CMVseropositive patients were included; however, this still captured 65% of all screened patients (data not shown). Future studies could focus on CMV-seronegative patients to better understand the impact of HHV-6 in the absence of CMV. Given the lack of an international standard for HHV-6 viral DNA detection, extrapolation of viral load data remains a limitation in all studies of HHV-6. It is possible that some patients had late undetected HHV-6 reactivation since we did not monitor patients after hospital discharge. Although this would not affect our results, it would mitigate our ability to ascribe a biologically significant impact of HHV-6 viremia in this study. However, we think this is unlikely, as HHV-6 viremia is uncommon outside the setting of critical illness or immunosuppression (21, 23, 
39)
, and the vast majority of first reactivation events occurred before day 30. Lastly, we recognize the heterogeneity in the ICU patients included in this study, and particularly the BICU patients, who have longer length of stays and may represent a unique population. However, we were unable to evaluate the BICU patients separately due to sample size. Our data should be interpreted in the context of the study design and are hypothesis generating. We are careful to emphasize that it is not possible to infer a causal link between HHV-6 and CMV coreactivation and the composite endpoint of this study. Although reactivation of herpesviruses in ICU patients has been hypothesized to represent a marker of illness severity, we did not find an association between at least one widely used marker for illness severity (APACHE II score) and reactivation of either HHV-6 or CMV, suggesting that factors beyond illness severity might be important. Given that additional viruses may reactivate in critically ill patients (23) and the association of viral coreactivation with adverse clinical outcomes reported here, future studies in larger CMV-seropositive and CMVseronegative ICU cohorts should be performed to define the mechanism(s) underlying this relationship and to determine if prevention or treatment of reactivating viruses leads to improved outcomes.
CONCLUSIONS
In summary, HHV-6 reactivation occurs frequently in immunocompetent ICU patients, often concurrently with CMV, and coreactivation of both viruses is independently associated with worse outcomes compared to no viral reactivation or reactivation of either virus alone. HHV-6B appeared to be the predominant species in our cohort. Although there are biologically plausible mechanisms by which viral reactivation could contribute to morbidity and/or mortality, randomized controlled treatment or prevention trials using agents active against both HHV-6 and CMV are needed to explore a causal link between viral reactivation and adverse outcomes in ICU patients. Adjusted for baseline variables of mechanical ventilation and ICU type, which retained significance in both models.
